Pangenomic Health Inc. (CNSX:NARA) signed an arm's length non binding Letter of Intent to acquire Mindleap Health Inc. from Mydecine Innovations Group Inc. (OTCPK:MYCO.F) for CAD 4 million on August 31, 2022. The LOI contemplates that the Pangenomic will acquire all of Mindleap's outstanding shares for a purchase price of CAD 4,000,000 (the 'Purchase Price'), payable by the issuance of units (each a 'Unit') at an agreed-upon price of CAD 0.20 per Unit (the 'Unit Price'), or such higher price as the Canadian Securities Exchange (the 'CSE') may require. PanGenomic entered into a definitive share exchange agreement dated November 18, 2022 with Mydecine Innovations Group and Mindleap Health Inc. to acquire all of the issued and outstanding shares of Mindleap. Pursuant to the Share Exchange Agreement, the Company will acquire all of Mindleap's outstanding shares for a purchase price of CAD 3,600,000, payable by the issuance of units of the Company at a price of CAD 0.20, or such greater price as may be required by the Canadian Securities Exchange ("CSE"), per Unit (the "Unit Price"). Each Unit will be comprised of one Class A Common Share of PanGenomic (a "Common Share") and one share purchase warrant (each a "Unit Warrant") to purchase one additional Common Share (a "Unit Warrant Share") at a price of CAD 0.30, or such greater price as may be required by the CSE, per Unit Warrant Share for 24 months from the closing of the Transaction (the "Closing"). Closing is subject to a number of customary conditions, including the approval of the CSE and the NEO, if required under the rules and policies of the CSE and the NEO. The Purchaser shall be satisfied with the results of its due diligence investigations relating to Mind.Leap, the Mind.Leap Shares and the Transaction, acting reasonably. Closing is anticipated to occur on or about November 30, 2022.

Pangenomic Health Inc. (CNSX:NARA) completed the acquisition of Mindleap Health Inc. from Mydecine Innovations Group Inc. (OTCPK:MYCO.F) on December 9, 2022. The consideration consists of 18 million units of Pangenomic Health. The board of directors approved a reduction of the exercise price of the warrants from CAD 0.30 per common share to CAD 0.20 per common share. In connection with the Transaction, Pangenomic Health issued 2 million units as a finder's fee and incurred acquisition costs of CAD 0.05 million. Each unit was comprised of one common share of Pangenomic Health and one share purchase warrant, which is exercisable at CAD 0.30 per share until December 9, 2024.